Scalper1 News
Big pharma Merck (MRK) released late-stage data Wednesday on its hepatitis C regime that met Wall Street’s expectations, and also announced that the FDA had awarded it breakthrough therapy designation for certain patient groups. Merck’s 14 studies were among a passel of newly released abstracts for presentations at the annual meeting of the European Association for the Study of Liver (EASL), convening April 22 to 26 in Vienna. The combination Scalper1 News
Scalper1 News